Risk factor
Very high price volatility
Profitability factor
Very weak growth
About
Boule Diagnostics AB (publ) operates as a diagnostic company specializing in the development, manufacturing, and commercialization of instruments and consumables designed for blood analysis. Its comprehensive product portfolio for human diagnostics includes a range of hematology analyzers, reagents, blood controls and calibrators, reagent rotors, and cleaning products, distributed under the Swelab, Medonic, and Quintus brand names. Furthermore, it provides veterinary hematology and clinical chemistry analyzer and diagnostic systems through its Exigo brand. Distribution is handled directly in Sweden and the United States, complemented by an international network of distributors. Boule serves a diverse client base encompassing hospitals, clinical laboratories, healthcare centers, veterinary clinics, and other diagnostic companies. The company maintains operational presences in Sweden, the United States, Mexico, and Russia. Established in 1956, Boule Diagnostics AB is headquartered in Spånga, Sweden.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is of fair value on EV/EBITDA, trading at neutral levels
Target Price
The average target price of BOUL.ST is 3.8 and suggests 15% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr